Health Trials

Chronic Myeloproliferative Disorders

3

Review clinical trials related to Chronic Myeloproliferative Disorders. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Registry of Older Patients With Cancer

RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

Participants needed: 3,000
Trial details
Age: 65+Biological sex: AllType: ObservationalSponsor: UNC Lineberger Comprehensive Cancer CenterUpdated: Jun 29, 2026Locations: 7
Eligibility criteria

Patients must have an appointment at the North Carolina Cancer Hospital and agre... [+2]

Read more
Status: Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.

Participants needed: 15,000
Trial details
Age: 18-120Biological sex: AllType: ObservationalSponsor: UNC Lineberger Comprehensive Cancer CenterUpdated: Oct 27, 2025Locations: 1
Eligibility criteria

Acute myeloid leukemia [+14]

Read more
Status: Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Trial details
Age: 18-120Biological sex: AllType: InterventionalSponsor: Barbara Ann Karmanos Cancer InstituteUpdated: Jul 8, 2025Locations: 1
Eligibility criteria

Histologically confirmed solid tumor or hematologic malignancy [+7]

Read more